Dr Agarwal's Health Care Share Price Today (AGARWALEYE)
TODAY IN ONE LINE
AGARWALEYE edged up 0.5% on light volume, in line with Nifty's 0.3% move, supported by recent strong earnings.
With a market cap of ₹15,630.43 Cr., it trades at a P/E of 115.95. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Dr Agarwal's Health Care flags
Key strengths and potential risks.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 20.8% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 22.6% and Profit up 14.9%
- ●Healthy Operating MarginsOPM is structurally strong at 27.4%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 6.8%
- ●Expensive ValuationTrading at a high P/E ratio of 112.1x
- ●FII SellingFII holding decreased by 1.13% QoQ
- ●Rising Receivables vs SalesReceivables grew 30.6% outpacing sales growth of 28.4%
What changed recently?
Recent events, corporate actions, and announcements.
Dr. Agarwal's Health Care Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Dr. Agarwal's Health Care Limited, framed against the sector median so the premium or discount is obvious at a glance.
Dr. Agarwal's Health Care Limited trades at a P/E of 115.95× and P/B of 7.62×.
Valuation
Profitability
Growth
Financial Health
Dr. Agarwal's Health Care Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Dr. Agarwal's Health Care Limited — derived from the live tape, not yesterday's close.
Dr. Agarwal's Health Care Limited last traded at ₹496 with an intraday range of ₹493.85–₹503 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹496.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 519.68 | +23.68 | +4.77% |
| R3 | 510.53 | +14.53 | +2.93% |
| R2 | 506.77 | +10.77 | +2.17% |
| R1 | 501.38 | +5.38 | +1.09% |
| PIVOT | 497.62 | 1.62 | 0.33% |
| CURRENT | 496.00 | — | — |
| S1 | 492.23 | -3.77 | -0.76% |
| S2 | 488.47 | -7.53 | -1.52% |
| S3 | 483.08 | -12.92 | -2.60% |
| S4 | 473.93 | -22.07 | -4.45% |
AGARWALEYE is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹493.85–₹503
Trading Inside opening range
Dr. Agarwal's Health Care Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Dr. Agarwal's Health Care Limited, switchable between annual and quarterly views, consolidated or standalone.
Dr. Agarwal's Health Care Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹15,630.43 Cr. and reported EPS of ₹4.16.
| Period | 2025 | 2026 |
|---|---|---|
| Revenue from Operations | 1,711 | 2,080 |
| Other Income | 46 | 44 |
| Total Income | 1,757 | 2,125 |
| Cost of Goods Sold (COGS) | 162 | 193 |
| Gross Profit | 1,549 | 1,887 |
| +Operating Expenses | 1,093 | 1,318 |
| EBITDA | 456 | 570 |
| +Non-Operating Expenses | 337 | 368 |
| Profit Before Tax (PBT) | 160 | 249 |
| +Tax Expense | 50 | 81 |
| Total Profit for Period | 110 | 168 |
| Less: Non-controlling Interests | 27 | 35 |
| Net Profit (Owner's PAT) | 83 | 133 |
| Earnings Per Share (EPS) | 2.64 | 4.20 |
| Diluted Shares Outstanding (Nos.) | 32 | 32 |
| +Additional Disclosures | 1,786 | 2,121 |
| Sales Growth % | — | 21.57 |
| YoY Sales Growth % | — | 21.57 |
| Material Cost % | 0 | 0 |
| Employee Cost % | 19 | 19 |
| Other Cost % | 45 | 44 |
| OPM % | 27 | 27 |
| Tax % | 31 | 32 |
| Profit Growth % | — | 59.59 |
| Gross Margin % | 90.53 | 90.73 |
| EBITDA Margin % | 26.67 | 27.38 |
| Interest Coverage Ratio | 2.07 | 3.24 |
| Ebit | 226 | 293 |
Dr Agarwal's Health Care segment analysis: revenue and profit mix.
Disclosed business segments at Dr Agarwal's Health Care with their share of revenue and profit, switchable between consolidated and standalone reporting.
Dr Agarwal's Health Care discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Dr. Agarwal's Health Care Limited.
Our AI distills the core fundamental drivers supporting Dr. Agarwal's Health Care Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Dr. Agarwal's Health Care Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 21.9% YoY despite competitive healthcare market pressures.
TTM revenue grew 22.6% YoY, outpacing sector peers and indicating robust demand.
Operating margin 14.10% TTM demonstrates strong operational efficiency and cost control.
Debt-to-equity 0.0053 maintains conservative leverage, supporting financial stability.
Operating cash flow ₹320.72 Cr exceeds PAT ₹39 Cr, signaling quality earnings conversion.
Key Risks.
P/E ratio 112.13x significantly elevated, pricing in aggressive growth expectations unsustainably.
Net profit margin 6.40% TTM ranks lowest among peers, constraining profitability potential.
ROE 6.81% and ROCE 11.10% lag peer benchmarks, reflecting suboptimal capital efficiency.
Zero dividend yield offers no income component, limiting appeal to yield-seeking investors.
52-week price return 0% indicates stagnant momentum despite strong earnings growth.
Flip Conditions.
Trim if P/E re-rates above 151. The valuation cushion thins from there.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Dr. Agarwal's Health Care Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Dr. Agarwal's Health Care Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Dr. Agarwal's Health Care Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Dr. Agarwal's Health Care Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Dr. Agarwal's Health Care Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Dr. Agarwal's Health Care Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Dr. Agarwal's Health Care Limited stood at 51.9% of traded volume, against a 20-day average of 49.1%.
Dr Agarwal's Health Care announcements: results, concalls, ratings, M&A.
Filings Dr Agarwal's Health Care sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Dr Agarwal's Health Care files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 119 documents below.
ESOP/ESOS/ESPS
Allotment of 43,155 Equity Shares pursuant to the exercise of options granted under Dr. Agarwal's Health Care Limited - Employees Stock Option Scheme…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026, is enclosed.
Trading Window
Dr. Agarwal's Health Care Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Disclosure under SEBI Takeover Regulations
DR. ADIL AGARWAL,Dr. Adil Agarwal Family Trust, Dr. Agarwal s Eye Institute, Dr. Agarwal s Eye Institute Private Limited , DR. AMAR AGARWAL, DR. AMAR…
Amalgamation/Merger
Dr. Agarwal's Health Care Limited has informed the Exchange about the Notice Convening Meeting Of The Unsecured Creditors Of The Company Pursuant To…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
Dr Agarwal's Health Care dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Dr Agarwal's Health Care has declared, sequenced by announce and record date.
Dr Agarwal's Health Care corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Dr. Agarwal's Health Care Limited: business, sector, key facts.
What Dr. Agarwal's Health Care Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Dr. Agarwal's Health Care Limited operates in the Hospital industry under the Healthcare sector, listed as NSE: AGARWALEYE, BSE: 544350.
Dr. Agarwal's Health Care Limited, operating under the name AGARWALEYE, is a prominent provider of comprehensive eye care services in India and abroad. Their business model centers around offering a wide spectrum of ophthalmic treatments and products, catering to diverse patient needs and preferences.
A significant portion of their revenue stems from surgical procedures. These include a comprehensive range of cataract surgeries, employing advanced techniques such as small incision cataract surgery, phacoemulsification, and even robotic cataract surgery. Beyond cataract care, they perform refractive surgeries to correct vision impairments and reduce or eliminate the need for corrective lenses. Further surgical offerings include retinal treatments, corneal transplants, oculoplasty (eyelid surgery), glaucoma surgeries, and pterygium removal.
Beyond surgical interventions, AGARWALEYE provides a robust suite of non-surgical services. These encompass diagnostic testing for various eye conditions, coupled with non-surgical treatments such as retinal laser therapy and dry eye treatments. The company also offers comprehensive consultation services, allowing patients to access expert ophthalmological advice and personalized care plans.
In addition to medical services, AGARWALEYE operates a retail arm, selling a range of products directly related to eye care. This includes eyeglasses, lenses, contact lenses, and frames, providing a convenient one-stop shop for patients requiring both treatment and optical products. They also sell eye care-related pharmaceutical products, further strengthening their integrated healthcare approach.
Established in 2010 and headquartered in Chennai, India, AGARWALEYE has steadily grown its presence both domestically and internationally, positioning itself as a key player in the global ophthalmology market. Their business strategy blends advanced surgical techniques, comprehensive non-surgical care, and a retail component to create a fully integrated eye care ecosystem.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Apollo Hospitals Enterprise (APOLLOHOSP) Share PricePeer
- Artemis Medicare Services (ARTEMISMED) Share PricePeer
- Aster DM Healthcare (ASTERDM) Share PricePeer
- Fortis Healthcare (FORTIS) Share PricePeer
- GPT Healthcare (GPTHEALTH) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Dr. Agarwal's Health Care Limited (AGARWALEYE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Dr. Agarwal's Health Care Limited (AGARWALEYE)?
The current share price of Dr. Agarwal's Health Care Limited (AGARWALEYE) is ₹496. Today, the stock has gained by ₹2.25 (0.46%), trading in a range of ₹493.85 to ₹503. The stock opened at ₹497.05 with a trading volume of 23,094 shares.
02Is Dr. Agarwal's Health Care Limited stock a good investment for long-term?
Dr. Agarwal's Health Care Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,630.43 crores, P/E ratio of 115.95, ROE of 6.81%, and ROCE of 11.10%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Dr. Agarwal's Health Care Limited stock?
The 52-week high price of Dr. Agarwal's Health Care Limited (AGARWALEYE) is ₹568, while the 52-week low is ₹401. Currently trading at ₹496, the stock is 56.9% away from its 52-week low and 12.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Dr. Agarwal's Health Care Limited stock at the current price?
Whether to buy Dr. Agarwal's Health Care Limited stock at ₹496 depends on multiple factors. The stock is currently trading with a P/E ratio of 115.95 and P/B ratio of 7.62. Today's performance shows a gain of 0.46%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Dr. Agarwal's Health Care Limited and when is the next dividend?
Dr. Agarwal's Health Care Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹496, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Dr. Agarwal's Health Care Limited?
Dr. Agarwal's Health Care Limited's key financial metrics include: P/E Ratio: 115.95, P/B Ratio: 7.62, ROE: 6.81%, ROCE: 11.10%, Dividend Yield: 0.00%, EPS: ₹4.16, Book Value: ₹63.76, and Debt-to-Equity: 0.01. The company's market cap stands at ₹15,630.43 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Dr. Agarwal's Health Care Limited stock performing today in the market?
Dr. Agarwal's Health Care Limited stock opened at ₹497.05 and is currently trading at ₹496, showing a gain of ₹2.25 (0.46%). The intraday high is ₹503 and low is ₹493.85. The trading volume stands at 23,094 shares, indicating moderate market participation today.
08What is the P/E ratio of Dr. Agarwal's Health Care Limited and what does it indicate?
Dr. Agarwal's Health Care Limited has a Price-to-Earnings (P/E) ratio of 115.95, which means investors are willing to pay ₹115.95 for every ₹1 of earnings. With an EPS of ₹4.16, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Dr. Agarwal's Health Care Limited (AGARWALEYE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.